Celldex Discontinues Barzolvolimab Development in Prurigo Nodularis After Phase 2 Failure
Celldex discontinues barzolvolimab development in prurigo nodularis after its Phase 2 study failed to meet the primary endpoint and key secondary endpoints.
/ 5 items
#CLDX↓
AbbVie Bolsters Immunology Pipeline with $10.9 Billion Apogee Acquisition
The acquisition would add a longer-acting alternative to Dupixent for inflammatory diseases.
Barclays Upgrades Celldex to Overweight, Raises Price Target to $45
Barclays boosts Celldex Therapeutics on strong drug outlook; higher success odds and sales expectations.
Wolfe Research Turns Bullish on Celldex, Upgrading to Outperform and Citing Stronger 2026 Catalysts
Wolfe Research upgrades Celldex Therapeutics to Outperform from Peer Perform, citing stronger 2026 catalysts and depressed valuation for rebound potential.
Celldex Ends Esophagitis Treatment, Explores Other GI Uses
Celldex stopped barzolvolimab for eosinophilic esophagitis after it failed to improve symptoms, despite depleting mucosal mast cells. The company will now explore other GI diseases driven by mast cells where the antibody might be effective.